Tech Center 1600 • Art Units: 1637
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18017093 | VARIANT TXNIP COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF DEGENERATIVE OCULAR DISEASES | Non-Final OA | President and Fellows of Harvard College |
| 18066878 | NUCLEOBASE EDITORS COMPRISING NUCLEIC ACID PROGRAMMABLE DNA BINDING PROTEINS | Final Rejection | President and Fellows of Harvard College |
| 17584176 | CONTROL OF MAMMALIAN GENE DOSAGE USING CRISPR | Non-Final OA | The Regents of the University of California |
| 18007378 | COMPOSITION AND METHOD | Non-Final OA | Cambridge Enterprise Limited |
| 18014561 | COMPOSITIONS AND METHODS FOR TARGETING TUMOR ASSOCIATED TRANSCRIPTION FACTORS | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 17637557 | DDX17 AND NLRC4 TARGETING FOR INFLAMMATORY DISEASES | Non-Final OA | University of Virginia Patent Foundation |
| 18190097 | COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE DISORDERS BY TARGETING H19X-ENCODED NON-CODING RNAS | Non-Final OA | University of Houston System |
| 17999680 | PHOSPHOROTHIOATE NUCLEIC ACID CONJUGATES INCLUDING DNA EDITING ENZYMES | Non-Final OA | CITY OF HOPE |
| 18023548 | COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION | Non-Final OA | VOR BIOPHARMA INC. |
| 17787809 | COMPOSITION FOR TRANSLATION, AND METHOD FOR PRODUCING PEPTIDE | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 17938857 | Compositions and Methods for Treating Huntington's Disease and Related Disorders | Final Rejection | The Children's Hospital of Philadelphia |
| 18016265 | GENE THERAPY FOR NEUROMUSCULAR AND NEUROMOTOR DISORDERS | Non-Final OA | UCL BUSINESS LTD. |
| 18161655 | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | Non-Final OA | TEAMEDON INTERNATIONAL, INC. |
| 18268594 | Treatment Schedule for Cytokine Proteins | Non-Final OA | BIONTECH SE |
| 18280338 | CODON-OPTIMIZED NUCLEIC ACID ENCODING THE FIX PROTEIN | Non-Final OA | JOINT STOCK COMPANY «BIOCAD» |
| 18264782 | GENETICALLY MODIFIED INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE THEREOF | Non-Final OA | Poseida Therapeutics, Inc. |
| 18266357 | NUCLEOTIDE SEQUENCE, EXPRESSION VECTORS, RECOMBINANT YEAST CELLS AND APPLICATIONS THEREOF | Non-Final OA | INDIAN INSTITUTE OF SCIENCE |
| 18274634 | GENE THERAPY FOR TREATING NEURODEGENERATIVE DISEASES | Non-Final OA | ABRAIN |
| 18274672 | GENE THERAPY FOR TREATING NEURODEGENERATIVE DISEASES | Non-Final OA | ABRAIN |
| 18221914 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | Non-Final OA | miCure Therapeutics Ltd. |
| 17656901 | MICRORNA OLIGONUCLEOTIDE THERAPEUTICS FOR OVARIAN CANCER | Non-Final OA | AptamiR Therapeutics, Inc. |
| 18247523 | RNA GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER RELATED HUMAN HERPESVIRUSES | Non-Final OA | Temple University - of the Commonwealth System of Higher Education |
| 18246575 | METHODS OF TREATING NEURONAL DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF | Non-Final OA | Generoath Co., Ltd. |
| 18020720 | IMPROVED GENE EDITING | Non-Final OA | University of Helsinki |
| 17918147 | CELL CLASSIFIER CIRCUITS AND METHODS OF USE THEREOF | Non-Final OA | Eidgenössische Technische Hochschule Zürich |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy